Mylan Announces Settlement Agreement in Patent Infringement Litigation Relating to Sunovion's Brovana® Product
Mylan Inc. (Nasdaq: MYL) today announced that Mylan Specialty L.P., f/k/a Dey Pharma, L.P., has entered into an agreement with Sunovion Pharmaceuticals Inc., f/k/a Sepracor Inc., to resolve the parties' patent litigation relating to Sunovion's Brovana® product.
The U.S. District Court for the Southern District of New York's Final Judgment and Order notes that the parties have entered into a settlement and license agreement and that Sunovion has acknowledged that two Mylan patents are valid, enforceable and infringed by Sunovion's Brovana® product. These patents expire on June 22, 2021. The terms of the parties' agreement are confidential.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.